A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Inclusion Criteria:

• Participant is currently diagnosed with and/or being treated for secondaryhyperparathyroidism (SHPT).

• Participant must be diagnosed with chronic kidney disease (CKD) stage 5 receivingperitoneal dialysis (PD) or hemodialysis (HD) for at least 30 days prior to initialScreening.

• For entry into the Washout Period (for vitamin D receptor activator [VDRA] non-naiveparticipants), the participant must meet the appropriate laboratory criteria basedupon the participant's age as described in the protocol.

• For entry into the Dosing Period (for VDRA-naive participants or VDRA non-naiveparticipants who have completed the Washout Period), the participant must meet theappropriate laboratory criteria based upon the participant's age as described in theprotocol.

Exclusion Criteria:

• Participant is scheduled to receive a living donor kidney transplant within 3 monthsof Screening or is a kidney transplant recipient.

• Participant is expected to discontinue peritoneal dialysis (PD) or hemodialysis (HD)within 3 months of the initial Screening visit.

• Participant has had a parathyroidectomy within 12 weeks prior to Screening.

• Participant is taking maintenance calcitonin, bisphosphonates, glucocorticoids (in adose equivalent to more than > 0.16 mg/kg/day or 5 mg prednisone/day, whichever islower), 4 weeks prior to Dosing.

• Participant is receiving calcimimetics at the time of Screening or is expected toinitiate calcimimetics at any time throughout the study.

• Participant is unable to take oral medications.